Market Overview

St. Jude Medical Received FDA Approval For MultiPoint Pacing Technology

Related STJ
Watch These 7 Huge Call Purchases In Wednesday Trade
Amid Headline Risk, Barclays Says St. Jude's Pipeline Underestimated
St. Jude shareholders back Abbott merger (Seeking Alpha)

Correction: An earlier version of this article's title stated the covered material was related to St. Jude Medical's FDA approval for treatment of chronic intractable pain of the limbs. This version has been updated. More information on St. Jude's other release is here.

Shares of St. Jude Medical, Inc. (NYSE: STJ) were trading higher by nearly 2 percent on Wednesday after the company announced the U.S. Food and Drug Administration approved its first-to-market MultiPoint Pacing technology featured on the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D), the Quadra Allure MP CRT-pacemaker (CRT-P) and two new quadripolar Quartet LV leads.

St. Jude Medical noted that its MultiPoint Pacing technology "enables a revolutionary approach and provides additional options, which may benefit CRT patients who are not responsive to other pacing alternatives." Approximately 23 million are afflicted with congestive heart failure and 2 million new cases are diagnosed worldwide each year.

"Having the ability to truly individualize cardiac resynchronization therapy is a significant step forward in the clinical approach to treating some of our most complex heart failure patients," said Dr. Gery Tomassoni, director of electrophysiology at Baptist Health Lexington in Lexington, Kentucky. "MultiPoint Pacing technology provides a new set of tools that can be non-invasively programmed in an attempt to improve CRT response, thus opening up an important new treatment option for many patients who may need it."

Posted-In: FDA Medical Companies MultiPoint Pacing st. jude medicalNews FDA


Related Articles (STJ)

View Comments and Join the Discussion!